Betagenon AB

Betagenon works with research and development of new drugs to treat type 2 diabetes and other diseases linked to obesity and sedentary. We focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Drugs that activate AMPK are also expected to have beneficial effects on metabolic and cardiovascular diseases and on certain cancers. We also have a close collaboration with Umeå University and the ground breaking research has in recent years led to international attention. The goal is to develop drugs that can prevent and/or cure diabetes and other diseases caused by our western lifestyle.

Contact: Thomas Edlund, CEO
Contact details
Uminova science park, Tvistevägen 48, SE-90748Umeå, Sweden
Phone: +4690 - 15 48 22